Roche Receives EU Approval for Venclyxto (venetoclax) plus MabThera (rituximab) to Treat Adults with CLL
Shots:
- The approval is based on the results of P-III MURANO study assessing Venclexta + MabThera (six cycles) vs (bendamustine + MabThera) (BR) (six cycles) in 389 patients in ratio (1:1) with 1L r/r CLL for two years
- P-III MURANO study results: mPFS 83%; no. of events (32 vs 114); ORR (93.3% vs 67.7%); CR/CRi (26.8% vs 8.2%); MRD-negativity in peripheral blood- bone marrow (62.5%- 15.5% vs 13.3%-1.0%)
- Venclyxto is a novel inhibitor of B-cell lymphoma-2 (BCL-2) protein- developed by Roche & AbbVie and is currently approved in 50 countries
Ref: Roche | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com